期刊
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
卷 37, 期 1, 页码 39-45出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijantimicag.2010.08.021
关键词
Solithromycin; Fluoroketolide; Telithromycin; Staphylococci; Enterococci; MLSB
资金
- Cempra Pharmaceuticals, Inc. (Chapel Hill, NC)
- Achaogen
- Anacor
- API
- Arpida
- ARYx
- Astellas
- AstraZeneca
- Avexa
- Bayer
- bioMerieux
- Becton Dickinson
- Cadence
- Cempra
- Cerexa
- Cornerstone BioPharma
- Cosmo Technologies
- Cubist
- Elan
- Enanta
- GlaxoSmithKline
- Johnson & Johnson (Ortho McNeil)
- LegoChem Biosciences Inc.
- Meiji Seika Kaisha
- Microphage Inc.
- MIGENIX
- Mpex
- Nabriva
- Novexel
- Novartis
- Optimer
- Ordway
- Paratek
- Pfizer (Wyeth)
- PPD Therapeutics
- Premier Research Group
- Protez
- Shionogi USA
- Medicines Co.
- Theravance
- TREK Diagnostics
- Vertex Pharmaceuticals
Solithromycin (CEM-101) is a novel fluoroketolide with high potency against Gram-positive and Gram-negative bacteria commonly associated with community-acquired respiratory tract infections and skin and skin-structure infections. In this study, solithromycin and comparator antimicrobials were tested against a contemporary collection of Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, Enterococcus faecium and other Enterococcus spp. collected in the SENTRY Antimicrobial Surveillance Program. Solithromycin was active against S. aureus [minimum inhibitory concentration for 50% of the organisms (MIC50) = 0.12 mu g/mL] and was two-fold more active than telithromycin (MIC50 = 0.25 mu g/mL). Solithromycin was more potent against meticillin (oxacillin)-susceptible S. aureus [MIC50 = 0.06 mu g/mL and MIC for 90% of the organisms (MIC90) = 0.12 mu g/mL) compared with meticillin (oxacillin)-resistant S. aureus (MIC50 = 0.12 mu g/mL and MIC90 > 16 mu g/mL). Solithromycin activity was reduced amongst heterogeneous vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus (MIC50 > 16 mu g/mL). Against strains with defined susceptibilities to erythromycin, clindamycin and telithromycin, solithromycin showed potent inhibition against all combinations (MIC50 = 0.06 mu g/mL) except those with non-susceptibility to telithromycin (> 2 mu g/mL) (MIC50 > 16 mu g/mL). The solithromycin MIC50 for E. faecium (1 mu g/mL) wasfour-fold higher than the MIC50 for E. faecalis (0.25 mu g/mL). In summary, solithromycin demonstrated high potency against many Staphylococcus and Enterococcus spp. isolated from contemporary infections worldwide. (C) 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据